

PROVIDER NOTIFICATION OF RETAIL DRUG POLICY CRITERIA CHANGE			
Drug Impacted	CRITERIA CHANGE	EFFECTIVE DATE	Formulary
<b>Omisirge</b>	Added coverage for the treatment of severe aplastic anemia (SAA) for members 6 years of age and older following reduced intensity conditioning therapy, per FDA label update.	2/22/2026	Essential
<b>Padcev</b>	Updated coverage for urothelial carcinoma in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph to align with NCCN and FDA label update.	2/22/2026	Essential Metallic
<b>Revuforj</b>	Added coverage for use in patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation, per FDA label update and NCCN. Documentation of NPM1 mutational status added for applicable submissions.	2/22/2026	Essential